Atherosklerose and arteriosclerosis in hypertension;Atherosklerose und arteriosklerose als hochdruckfolgen

Nieren- und Hochdruckkrankheiten

Volumn 29, Issue 1, 2000, Pages 1-16

  Klaus, D ^a  

^a NONE   (Germany)

Author keywords

Age and arteriosclerosis; Arterial compliance; Arterial distensibility; Arterial stiffness; Bioavailability of nitric oxide; Blood pressure augmentation; Hypertension and arteriosclerosis; Hypertension and atherosclerosis; Hypertension and endothelial dysfunction; Mechanotransduction; Pulse wave velocity; Superoxiddismutase in hypertension

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANTIOXIDANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC ACID DERIVATIVE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

AORTA PRESSURE; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; HYPERTENSION; PULSE PRESSURE; PULSE WAVE; REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 0033949987     PISSN: 03005224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Asmar R., J.A. Topouchian, A. Benetos, F.A. Sayegh, J.J. Mouraud, M.E. Safar: Non-invasive evalution of arterial abnormalities in hypertensive patients. J. Hypertension 15 (Suppl. 2), S99-S107 (1997).
2. Benetos A., St. Laurent, R.G. Asmar, P. Lacolley: Large artery stiffness in hypertension. J. Hypertension 15 (Suppl. 2), S89-S97 (1997).
3. Blacher J., G.M. London, M.E. Safar, J.J. Mourad: Influence of age and end-stage renal disease on the stiffness of carotid wall marterial in hypertension. J. Hypertension 17, 237-244 (1999).
4. Bonnardereaux A., E. Davies, X. Jeneumaitre et al.: Angiotensin II type 1 receptor gene polymorphism in human essential hypertension. Hypertension 24, 63-69 (1994).
5. Burnett jr. J.C.: Vasopeptidase inhibition: a new concept in blood pressure management. J. Hypertension 17 (Suppl. 1), S37-S43 (1999).
6. Chappey O., C. Dosquet, M.-P. Wantier, J.L. Wantier: Advanced glycation end products, oxidant stress and vascular lesions. Europ. J. Clin. Invest. 27, 97-108 (1997).
7. Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 265, 3255-3264 (1991).
8. Dzau V.J.: Angiotensin-converting enzyme as a multimechanistic factor in CAD. J. Myocard. Ischemia 7 (Suppl. 1), 6-14 (1995).
9. Eliasson M., J.-H. Jansson, P. Nilsson, K. Asplund: Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden. J. Hypertension 15, 349-356 (1997).
10. Fornes P., C. Richter, E. Vacher et al.: Losartan's protective effect in stroke prone spontaneously hypertensive rats persist durably after treatment withdrawal. J. Cardiovasc. Pharmacol. 22, 305-313 (1993).
11. Gibbons G.H.: Vasculoprotective and cardioprotective mechanisms in angiotensin converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide. Clin. Cardiol. 20 (Suppl. II), II-18-II-25 (1997).
12. Hansson L., L.H. Lindholm, L. Niskanen et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353, 611-616 (1999).
13. Hansson L., A. Zanchetti, S.G. Carruthers, B. Dahlöf et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension. Lancet 351, 1755-1762 (1998).
14. Harrison D.G.: Endothelial function and oxidant stress. Clin. Cardiol. 20 (Suppl. II), II-11-II-17 (1997).
15. Hayoz D., B. Rutschmann, F. Perret, M. Niederberger: Conduit artery compliance and distensibility are not necessarily reduced in hypertension. Hypertension 20, 1-6 (1992).
16. Hermandez-Presa M., C. Bustos, M. Ortego, J. Tunon et al.: Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein expression, and macrophage infiltration in a rabbit model on early atherosclerosis. Circulation 95, 1532-1541 (1997).
17. Holtz J., R.M. Goetz: The endothelium and the renin-angiotensin-system. Arzneimittelforschung 44 (1), 397-402 (1994).
18. Intengan H.D., E.L. Schiffrin: Role of endothelium on structural changes of small arteries in hypertension: effects of therapeutic intervention. J. Hypertension 16 (Suppl. 8), S97-S101 (1998).
19. Intersalt Cooperation Research Group: Intersalt: an international study of eletrolytes and blood pressure. Brit. Med. J. 297, 319-328 (1988).
20. Jeneumaitre X., F. Soubier, V. Kotelevtsev, R.P. Lifton, C.S. Williams et al.: Molecular basis of human hypertension: role of angiotensinogen. Cell 71, 169-180 (1992).
21. Khder Y., S. Briancou, R. Peterman, D. Quilliot et al.: Shear stress abnormalities contribute to endothelial dysfunction in hypertension but not in type II diabetes. J. Hypertension 16, 1619-1625 (1998).
22. Klaus D.: Vorschlag zur Einteilung und Klassifizierung der chronischen arteriellen Hypertonie. Dtsch. med. Wschr. 112, 483-484 (1987).
23. Klaus D., D. Wetzchewald, F. Saul, G. Obermeier, F. Lambers: Vergleich von direkter invasiver Blutdruckmessung mit indirekter Blutdruckmessung mittels Oscillometrie oder Sphygmomanometrie. Nieren- und Hochdruckkrankheiten 20, 160-169 (1991).
24. Kotchen Th.A., J.M. Kotchen, I.M. O'Shanghnessy: Insulin and hypertensive cardiovascular disease. Curr. Opinion in Cardiology 11, 483-489 (1966).
25. Lacka B., W. Grzesczak, K. Strojek, K. Twardowska-Sancha: Lipidperoxydation, Aktivität antioxydativ wirkender Enzyme und Spurenelementkonzentration bei Patienten mit primärer Hypertonie. Nieren- und Hochdruckkrankheiten 26, 69-74 (1997).
26. Lacy F., D.T. O'Connor, G.W. Schmid-Schönbein: Plasma hydrogen peroxide production in hypertensive and normotensive subjects at genetic risk of hypertension. J. Hypertension 16, 291-303 (1998).
27. Laurenzi M., A. Mancini, J. Menotti, R. Stamler, M. Frevisan, A. Zanchetti: Multiple risk factors in hypertension: results from the Gubbio study. J. Hypertension 8 (Suppl. 20), 7-12 (1990).
28. Li J.S., R. Lariviere, E.L. Schiffrin: Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24, 183-188 (1994).
29. London G.M., T.B. Drüeke: Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int. 51, 1687-1695 (1997).
30. Lüscher T.F. et al.: Endotheliale Dysfunktion und Stickstoffmonoxid. Internist 38, 411-419 (1997).
31. MacMahon S.: Antihypertensive drug treatment: the potential, expected and observed effects on vascular disease. J. Hypertension 8 (Suppl. 7), S239-S244 (1988).
32. MacMahon S., R. Pato, J. Cutler, R. Collins et al.: Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure. Lancet 335, 765-774 (1990).
33. Mahomed F.: zit. nach O'Rourke [45].
34. Mancini G.B.J., G.C. Henry, C. Macaya et al.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND study. Circulation 94, 258-265 (1996).
35. Mangoni A.A., L. Mircoli, L.M. Giannattasio, A.U. Ferrari, G. Mancia: Heart rate-dependence of arterial distensibility in vivo. J. Hypertension 14, 897-901 (1996).
36. McVeigh G.E., D.E. Burns, S.M. Finkelstein, J.N. Cohn et al.: Reduced vascular compliance as a marker for essential hypertension. Am. J. Hypertension 4, 245-251 (1991).
37. Mizutani K., K. Ikeda, Y. Kawai, Y. Yamori: Biochemical properties and chemical composition of the aorta in genetic hypertensive rats. J. Hypertension 17, 481-487 (1999).
38. Müller-Wieland D., J. Kotzka, B. Knebel, W. Krone: Metabolic syndrome and hypertension: pathophysiology and molecular basis of insulin resistance. Basic Res. Cardiol. 93 (Suppl. 2), 131-132 (1998).
39. Muller J.E., P.H. Stone, Z.G. Turi, J.D. Rutherford et al.: Circadian variation in the frequency of onset of acute myocardial infarction. New Engl. J. Med. 313, 1315-1322 (1985).
40. Mulvany M.J.: The structure of the resistance vasculature in essential hypertension. J. Hypertension 5, 129-136 (1987).
41. Nakai K., C. Itoh, Y. Minra, K. Hotta, T. Musha et al.: Deletion polymorphism of the angiotensin I-converting enzyme is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation 20, 1999-2202 (1994).
42. Nickenig G., O. Jung, K. Strehlow, B.A. Schölkens, M. Böhm: Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am. J. Physiol. 272, H2701-H2707 (1997).
43. O'Rourke M.F.: Arterial stiffness, systolic blood pressure and logical treatment of arterial hypertension. Hypertension 15, 339-347 (1990).
44. O'Rourke M.F., D.E. Gallagher: Pulse wave analysis. J. Hypertension 14 (Suppl. 5), S147-S157 (1966).
45. O'Rourke M.F., G. Mancia: Arterial stiffness. J. Hypertension 17, 1-4 (1998).
46. Palmer J.R., L. Rosenberg, S. Shapiro: Stature and the risk of myocardial infarction in women. Am. J. Epidemiol. 132, 27-32 (1990).
47. Panza J.A., C. Cardillo: Potential mechanisms of endothelial dysfunction in patients with essential hypertension. J. Hypertension 16 (Suppl. 8), S43-S48 (1998).
48. Panza J.A., R.R. Casino, C.M. Kilcoyne, A.A. Quyyumi: Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 87, 1468-1474 (1993).
49. Pepine C.: Endothelial dysfunction and its role in the cycle of cardiovascular disease. Can. J. Cardiol. 14 (Suppl. D), 5D-10D (1998).
50. Pitt B., R. Segal, F.A. Martinez, G. Meurers et al.: Randomised trial of Iosartan versus captopril in patients over 65 with heart failure. Lancet 349, 747-752 (1997).
51. Riede U.N., H.E. Schaefer: Allgemeine und spezielle Pathologie. 4. Aufl. Thieme, Stuttgart 1995.
52. Ruschitzka F., R. Corti, G. Noll, Th.F. Lüscher: A rationale for treatment of endothelial dysfunction in hypertension. J. Hypertension 17 (Suppl. 1), S25-S35 (1999).
53. Sacks F.M., M.A. Pfeffer, L.A. Moye et al.: The effect of pravastation on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 335, 1001-1009 (1996).
54. Safar M.E.: Representativeness of peripheral blood pressure values: the pulsatile component of blood pressure in hypertension. Z. Kardiol. 85 (Suppl. 3), 51-59 (1996).
55. Safar M.E., J.Ph. Siche, J.M. Mallion, G.M. London: Arterial mechanics predict cardiovascular risk in hypertension. J. Hypertension 15, 1605-1611 (1997).
56. Saul F., Y. Aristidou, D. Klaus, A. Wiemeyer, B. Lösse: Vergleich von invasiver Blutdruckmessung in der Aorta mit indirekter oszillometrischer Blutdruckmessung an Handgelenk und Oberarm. Z. Kardiol. 84, 675-685 (1995).
57. Schernthaner G.: Metabolisches Syndrom. In: Klaus D.: Manuale hypertonologicum. Dustri, Deisenhofen 1997.
58. Sebekova K., R. Schinzel, G. Münch, Z. Krivosikova, K. Dzurik, A. Heidland: Effect of Losartan on AGEs and TGF-β concentrations in the rat remnant kidney model. Kidney Blood Press. Res. 21, 336-398 (1998).
59. Sheperd J., S.M. Cobbe, C.G. Isles et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterinemia. The West of Scotland Coronary Prevention Study Group. New Engl. J. Med. 333, 1301-1307 (1995).
60. Siffert W.: G Proteins, hypertension, and coronary heart disease - novel findings and hypotheses. Kidney and Blood Press. Res. 19, 71-80 (1996).
61. Sorensen K.E., I.B. Kristensen, D.S. Celermajer: Atherosclerosis in the human brachial artery. J. Am. Coll. Cardiol. 29, 318-322 (1997).
62. Staessen J.A., R. Fagard, L. Thijs et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350, 757-764 (1997).
63. Taddei S., A. Virdis, P. Mattei, A. Salvetti: Endothelium-dependet forearm vasodilatation is reduced in normotensive subjects with a family history of hypertension. J. Cardiovasc. Pharmacol. 20 (Suppl. 12), S193-S195 (1992).
64. Takazawa K., F.M. O'Rourke, M. Fujita et al.: Estimation of ascending aortic pressure from radial arterial pressure using a generalised transfer function. Z. Kardiol. 85 (Suppl. 3), 137-139 (1996).
65. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853 (1998).
66. Vaughan D.E.: The renin-angiotensin system and fibrinolysis. Am. J. Cardiol. 79 (5A), 12-16 (1997).
67. Virdis A., L. Ghiadoni, I. Sudano, St. Taddei, A. Salvetto: Effect of antihypertensive drugs on endothelial function in humans. J. Hypertension 16 (Suppl. 8), S103-S110 (1998).
68. Watanabe H., S. Ohtsuka, M. Kakihana, Y. Sugishita: Coronary circulation in dogs with an experimental decrease in arterial compliance. J. Am. Coll. Cardiol. 21, 1497-1506 (1993).
69. Williams B.: Mechanical influences on vascular smooth muscle cell function. J. Hypertension 16, 1921-1929 (1998).
70. 1999 World Health Organization - International Society of Hypertension: Guidelines for the management of hypertension. J. Hypertension 17, 151-183 (1999).
71. WHO Monica Project: Geographical variation in the major risk factors of coronary heart disease in men and women aged 34-64 years. Wld. Hlth. Statist. Quart. 41, 115-138 (1988).